Sustained release

High melting point lipid excipients are used to sustain and delay drug release by the formation of a lipid matrix or barrier coating. Providing ease of use and scope for innovation, these lipids offer advantages in direct compression and in coating and extrusion techniques.

 

Compritol® 888 ATO is the ideal excipient for the development of sustained release dosage forms. It offers an interesting alternative to a hydrophilic matrix since it provides high resistance to physiological conditions (pH changes and digestion), is not associated with alcohol-related 

dose dumping and it can be used to minimize the burst-out effect encountered with highly water soluble drugs.

Standard processing techniques applicable for our excipients include:

    * melt granulation/pelletization

    * spray cooling

    * hot melt coating and melt extrusion

    * capsule molding

The development of multiparticulate and multilayered modified release tablets and solid lipid nanoparticles (SLN) 

and nanostructured lipid carriers (NLC) provide new horizons for innovation in modified release drug delivery technology.

Our ‘Formulation Guidelines for the Development of Sustained Release Tablets

 with Compritol® 888 ATO’ is available on the website and more

 information on processing techniques can be found in the Formulation Techniques 

section.

Compritol® 888 ATO is the ideal excipient for the development of sustained release dosage forms. It offers an interesting alternative to a hydrophilic matrix since it provides high resistance to physiological conditions (pH changes and digestion), is not associated with alcohol-related dose dumping and it can be used to minimize the burst-out effect encountered with highly water soluble drugs.

 

Standard processing techniques applicable for our excipients include:

- melt granulation/pelletization

- spray cooling

- hot melt coating and melt extrusion

- capsule molding

 

The development of multiparticulate and multilayered modified release tablets and solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) provide new horizons for innovation in modified release drug delivery technology.

 

Our ‘Formulation Guidelines for the Development of Sustained Release Tablets with Compritol® 888 ATO’ is available on the website and more information on processing techniques can be found in the Formulation Techniques section.

 


Legal noticesCreditsSite mapTerms & Conditions

© 2010 Gattefossé